Barclays analyst Peter Lawson lowered the firm’s price target on Arvinas to $26 from $39 and keeps an Overweight rating on the shares. The analyst is encouraged by the efficacy data for the company’s second generation AR degrader ARV-766 and is awaiting durability data. The firm removed the company’s first generation AR degrader bavdeg from its model given the de-prioritization.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ARVN:
- Wedbush upgrades Arvinas to Outperform on potential of ARV-766
- Arvinas price target lowered to $55 from $70 at Piper Sandler
- Arvinas upgraded to Outperform from Neutral at Wedbush
- Arvinas presents interim data from Phase 1/2 clinical trial for bavdegalutamide
- Potential of Arvinas’ PROTAC® AR Degraders Reinforced by 11.1 months rPFS with Bavdegalutamide and Updated Positive Interim Data from Second Generation ARV-766 in mCRPC